3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Unknown
1
Terminated
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
2
Neoplasm, Residual
1
NSCLC
1
Liver Neoplasms
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Hepatocellular
1
Interventions
Imatinib Mesylate
17
Dasatinib
8
nilotinib
7
Cytarabine
5
Hydroxyurea
4
ponatinib
3
Peripheral Blood Stem Cell Transplantation
3
Interferon-alpha
3
bosutinib
2
Surveys and Questionnaires
2
Stem Cell Transplantation
2
Radiotherapy
2
Polymerase Chain Reaction
2
Pioglitazone
2
Idarubicin
2
Cytogenetic Analysis
2
Busulfan
2
Antilymphocyte Serum
2
thymoglobulin
1
peginterferon alfa-2a
1
flumatinib
1
fludarabine phosphate
1
Tyrosine Kinase Inhibitors
1
Therapeutics
1
Registries
1
Psychiatric Rehabilitation
1
Patient Reported Outcome Measures
1
PF-114
1
Mycophenolic Acid
1
Mitoxantrone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
Tyrosine Kinase Inhibitors
×
Clear all
NCT02687425
2016-02-22
SESPI
Tongji Hospital
Phase 2
Unknown
20 enrolled